Company
Merck & Co Inc
NYSE:MRK
Merck & Co Inc is a global healthcare company. The company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products.
138 stories · page 3 of 7
Merck’s COVID-19 pill authorised for emergency use by US FDA
The Emergency Use Authorisation is for treatment of high-risk adults with mild to moderate COVID-19
Merck's new COVID pill gets the US regulatory green light - but only just
The Food & Drug Administration sign-off light follows the decision by regulators in the UK and EU to allow molnupiravir to be prescribed on an emergency use basis
Merck’s COVID drug not as effective as first thought
The company had reported it reduced the risk of serious illness by half in October
Merck Covid-19 treatment approved in UK as infection rate soars
Molnupiravir will be branded as Lagevrio in Britain
Antiviral drug from Merck slashes risk of Covid hospitalization or death
An application is being made to the US regulator for emergency use authorisation for what will be the first antiviral on the market to treat Covid-19
US stocks close higher on Merck's new COVID-19 oral treatment announcement
The drugmaker said the oral antiviral treatment reduced the risk of hospitalization or death by 50% for patients with mild or moderate cases
Archive
Traders send the S&P 500 to a record on busiest day of earnings season
11 of the S&P 500 components are scheduled to issue quarterly reports
Merck to invest US$1bn in Seattle Genetics as part of oncology collaboration agreement
Merck will buy 5mln shares at US$200 each plus other payments to study Seattle Genetics' candidate with its Keytruda treatment
Investments and investor services
IPO Roundup: Peloton Therapeutics gobbled up by Merck just as it prepared to go public
The sale provides Peloton shareholders with $1.05 billion in cash, with a possible $1.15 more if its treatments hit certain milestones
Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer
The Phase 2 study will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo and involve up to 60 patients
Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome
The company said results of a recent Stanford University diagnostic test of 20 patients with MF/CFS were 'impressive'
IPO Roundup: Tradeweb Markets and Silk Road Medical jump in market debuts, while NGM Biopharmaceuticals dips
Despite a slow start, 2019 is shaping up to be a stellar year for US initial public offerings with strong investor appetite for new issues
AstraZeneca granted Breakthrough Therapy Designation for rare genetic condition treatment
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious condition and have shown promise in early-stage clinical trials
Hemispherx Biopharma takes cancer war to new stage with drug Ampligen
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
CytoDyn presses forward with HIV treatment after Phase 3
Leronlimab is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
AFTER-HOURS MOVERS: Kraft shares plummet after earnings miss, discloses SEC subpoena
Also moving after-hours on Thursday was Zillow, which announced CEO Spencer Rascoff will step down